Pembrolizumab in Triple-Negative Breast Cancer
- PMID: 36239656
- DOI: 10.1056/NEJMc2210919
Pembrolizumab in Triple-Negative Breast Cancer
Comment in
-
Pembrolizumab in Triple-Negative Breast Cancer. Reply.N Engl J Med. 2022 Oct 13;387(15):1436. doi: 10.1056/NEJMc2210919. N Engl J Med. 2022. PMID: 36239658 No abstract available.
Comment on
-
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources